Pausing implementation of 340B insulin price pass-through
Joint statement on the Biden Administration regulatory freeze
DLC & DPAC responded to the Administration’s announcement pausing implementation of federal regulations that were not yet in effect on Inauguration Day.
The announcement was expected but many people in the diabetes community expressed concern because the Executive Order on Access to Life-Saving Medications was included in rules delayed for 60-days, moving implementation back to March 22, 2021.
Once the Biden Administration has reviewed the executive order and final rule, we hope they will agree unemployed, uninsured and underinsured Americans who rely on the nation’s safety net providers should benefit from deeply discounted 340B prices.
Insulin is available through 340B for pennies per unit. We recognize most 340B entities extend those savings to most of their patients, but insulin is an essential medicine and should be available at or below net cost to all eligible patients, particularly in the midst of a global pandemic and public health emergency.
We will continue working with policymakers on both sides of the aisle to advance policies that strengthen the nation’s public health care system, and secure effective, affordable, individualized care for every person with diabetes.
The DLC in Action
Learn about our commitment to important topics, including: